Answers are grounded in this paper and cite their sources.
The human ribonuclease/angiogenin inhibitor (RNH1) is a horseshoe-shaped, leucine-rich repeat protein that inhibits the activity of pancreatic-type ribonucleases (RNases). The binding of RNH1 to its target RNases is among the tightest interactions known in biology. RNH1 is also rich in cysteine (Cys), which must be reduced for RNH1 to maintain its structure and inhibitory function. The goal of this work is to dissect the significance of clusters of Cys residues to better understand the structure and stability of RNH1 and its role as an oxidative sensor in the cell. To achieve this goal, we engineered variants of RNH1 with some or all Cys substituted with leucines and incorporated a cleavable N-terminal twin Strep-tagⓇ. We expressed wtRNH1 in CHO-K1 cells and purified the protein using StrepTactinⓇ XT resin. Preliminary results show that our purified RNH1 is properly folded and able to inhibit RNase A. Our current work focuses on purifying wt and variant RNH1 and characterizing their structural stability, sensitivity to oxidation, and inhibition of target RNases. The biochemical properties of variant RNH1 will enable us to decipher the role of Cys in its structure and function in vitro and provide tools for investigating these questions in vivo. The Lawrence University Chandler Senior Experience is the main source of funding for this research.
No takes yet. Share an insight, caveat, or question.
Montalvo-Mosso et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: